| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -5,530 | -5,000 | -3,560 | -4,520 | -2,550 |
| Net Income Growth | -10.60% | -40.45% | +21.24% | -77.25% | -45.71% |
Protagenic Therapeutics Inc (PTIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Protagenic Therapeutics, Inc. is a biotechnology company. It focused on the discovery, research and development of novel and naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. Protagenic Therapeutics, Inc., formerly known as Atrinsic, Inc., is based in New York, United States.
Fiscal Year End Date: 12/31